Drug Trial Radar · NCT07124013
A Study of Olomorasib (LY3537982) in Healthy Japanese Participants
Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
191
Actual
Start
Sep 16, 2025
Primary completion
Jan 5, 2026
Study completion Jan 5, 2026
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Aug 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare and see how food affects the amount of olomorasib in the blood when olomorasib is taken in two different capsule forms. Participation in the study will last approximately 6 weeks.
Conditions
- Healthy
Interventions
OlomorasibDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK): Maximum Concentration (Cmax) of OlomorasibTime frame: Day 1 (Predose) through Day 7 (72 Hours Postdose)
- PK: Area under the Concentration versus Time Curve from Time Zero to Time t (AUC[0-tlast]) of OlomorasibTime frame: Day 1 (Predose) through Day 7 (72 Hours Postdose)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Souseikai Fukuoka Mirai Hospital
Fukuoka, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.